Market Access News | pharmaphorum

News

EFPIA warns EU reforms will hamstring pharma R&D

A trade organisation representing European pharmaceutical companies warned today that the European Commission’s proposed reforms to pharma legislation could result in the

News

Imfinzi faces Keytruda competition in biliary tract cancer

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch

News

X4 cues up FDA verdict in April for WHIM syndrome drug

The FDA has started a priority review of X4 Pharma’s mavorixafor, angling to become the first therapy for the rare disease WHIM syndrome, with a decision due by 30th April

News

MHRA imposes restrictions on acne drug in children

The UK medicines regulator has tightened up controls on the prescription of acne treatment isotretinoin to patients under the age of 18, following a review prompted by con

News

FDA clears Roche’s Vabysmo for retinal vein occlusion

Roche has claimed a third approval from the FDA for its eye disease therapy Vabysmo – already its fastest-growing product – that could make it an option for hundreds of th

News

Lilly finally gets FDA OK for ulcerative colitis drug Omvoh

After an earlier rejection, the FDA has approved Eli Lilly’s first-in-class IL-23p19 inhibitor mirikizumab as a treatment for adults with moderately to severely active ulc

EFPIA warns EU reforms will hamstring pharma R&D

Imfinzi faces Keytruda competition in biliary tract cancer

X4 cues up FDA verdict in April for WHIM syndrome drug

MHRA imposes restrictions on acne drug in children

FDA clears Roche’s Vabysmo for retinal vein occlusion

Lilly finally gets FDA OK for ulcerative colitis drug Omvoh

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks